Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

453.66 -1.30 (-0.29%)

Streaming Delayed Price Updated: 9:55 AM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

69 70 Next >

Investing Trends to Follow in 2024 ↗

January 06, 2024

We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one.

Via The Motley Fool

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2 Biotech Stocks With Huge Catalysts in 2024 ↗

January 05, 2024

Important clinical-trial readouts on the way could send these stocks soaring in early 2024.

Via The Motley Fool

Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors ↗

January 04, 2024

Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent.

Via InvestorPlace

Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture? ↗

December 27, 2023

Via Benzinga

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗

December 27, 2023

With a new medicine on the market and plenty of money, Vertex is in great shape.

Via The Motley Fool

Will the Biotech sector sustain its momentum in 2024?

January 04, 2024

The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Via MarketBeat

Topics ETFs

The Best Stocks to Invest $1,000 in Right Now ↗

January 04, 2024

It's not too late to get in on these market beaters.

Via The Motley Fool

Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics ↗

January 04, 2024

CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.

Via The Motley Fool

3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition ↗

January 03, 2024

Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside.

Via InvestorPlace

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High

January 03, 2024

Via Investor Brand Network

January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway. ↗

January 03, 2024

These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly.

Via The Motley Fool

Topics Stocks

Market Whales and Their Recent Bets on VRTX Options ↗

December 22, 2023

Via Benzinga

How Is The Market Feeling About Vertex Pharmaceuticals? ↗

December 21, 2023

Via Benzinga

3 Biotech Stocks Set for Breakthroughs in 2024 ↗

January 02, 2024

With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.

Via InvestorPlace

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

Prediction: These 3 Stocks Will Soar in 2024 ↗

January 01, 2024

Investors could enjoy an especially happy new year with these great stocks.

Via The Motley Fool

1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 ↗

December 31, 2023

Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.

Via The Motley Fool

Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade. ↗

December 30, 2023

These stocks offer attractive risk-reward profiles.

Via The Motley Fool

2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now ↗

December 29, 2023

It's been a crazy year across sectors, but winners remain.

Via The Motley Fool

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

3 Monster Stocks to Buy Without Any Hesitation ↗

December 27, 2023

These are easy choices for investors seeking market-beating long-term gains.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 25, 2023

Via Benzinga

3 Top Stocks to Buy Hand Over Fist Before the End of 2023 ↗

December 25, 2023

These are ideal stocks to buy sooner rather than later.

Via The Motley Fool

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗

December 23, 2023

Editas isn't out of the woods yet, but it's better off than before.

Via The Motley Fool

1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗

December 23, 2023

The stock has been in the news lately.

Via The Motley Fool

5 Top Stocks to Buy With Your End-of-the-Year Bonus ↗

December 23, 2023

Your bonus could become the gift that keeps on giving.

Via The Motley Fool

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗

December 22, 2023

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Via The Motley Fool

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗

December 22, 2023

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Via The Motley Fool

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ ↗

December 21, 2023

It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."

Via InvestorPlace

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.